Detalhe da pesquisa
1.
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
Blood
; 135(8): 534-541, 2020 02 20.
Artigo
Inglês
| MEDLINE | ID: mdl-31877211
2.
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study.
Haematologica
; 107(10): 2356-2364, 2022 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35385922
3.
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Br J Haematol
; 193(2): 271-279, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33403687
4.
Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?
Int J Mol Sci
; 22(13)2021 Jun 30.
Artigo
Inglês
| MEDLINE | ID: mdl-34209376
5.
The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities.
Int J Mol Sci
; 22(13)2021 Jun 25.
Artigo
Inglês
| MEDLINE | ID: mdl-34202238
6.
Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy.
Int J Mol Sci
; 21(11)2020 Jun 02.
Artigo
Inglês
| MEDLINE | ID: mdl-32498255
7.
Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis.
Hematol Oncol
; 42(3): e3277, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38682493
8.
Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia.
Am J Hematol
; 99(4): 759-762, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38314531
9.
Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.
Int J Mol Sci
; 20(24)2019 Dec 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31817512
10.
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.
Mol Cancer
; 17(1): 49, 2018 02 19.
Artigo
Inglês
| MEDLINE | ID: mdl-29455643
11.
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
Blood
; 127(6): 703-12, 2016 Feb 11.
Artigo
Inglês
| MEDLINE | ID: mdl-26603839
12.
Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis.
Pharmacol Res
; 131: 244-254, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29427770
13.
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage.
J Cell Biochem
; 118(11): 3968-3975, 2017 11.
Artigo
Inglês
| MEDLINE | ID: mdl-28401599
14.
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia.
Haematologica
; 102(9): 1530-1536, 2017 09.
Artigo
Inglês
| MEDLINE | ID: mdl-28572163
15.
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
BMC Cancer
; 17(1): 523, 2017 Aug 05.
Artigo
Inglês
| MEDLINE | ID: mdl-28779753
16.
What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?
Hematol Oncol
; 35(4): 420-423, 2017 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-27435333
17.
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Am J Hematol
; 92(8): 797-805, 2017 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-28466557
18.
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.
Am J Hematol
; 92(1): 82-87, 2017 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-27770583
19.
Present and future of molecular monitoring in chronic myeloid leukaemia.
Br J Haematol
; 173(3): 337-49, 2016 05.
Artigo
Inglês
| MEDLINE | ID: mdl-26947577
20.
Best Practices in Chronic Myeloid Leukemia Monitoring and Management.
Oncologist
; 21(5): 626-33, 2016 05.
Artigo
Inglês
| MEDLINE | ID: mdl-27032870